Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | GLA | P06280 | 3/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18224721 | 0.84 | KDM4E (0.54) | KDM4EALDH1A1GAAGLANOS3 | |
| SCHEMBL12633740 | 0.83 | NUDT1 (0.56) | KDM4EALDH1A1NOS3NOS2HSD17B10 | |
| SCHEMBL21749959 | 0.82 | KDM4E (0.53) | KDM4EALDH1A1GAAGLAHSD17B10 | |
| Acetic Acid Methyl Ester SCHEMBL28120651 | 0.82 | ATR (0.43) | KDM4EALDH1A1GAAGLANOS3 | |
| SCHEMBL13041779 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1GAAGLAHSD17B10 | |
| SCHEMBL27497167 | 0.81 | NOS3 (0.43) | KDM4EALDH1A1GAAGLANOS3 | |
| SCHEMBL31032953 | 0.81 | KDM4E (0.51) | KDM4EALDH1A1GAAGLAHSD17B10 | |
| SCHEMBL3630664 | 0.81 | GAA (0.51) | KDM4EALDH1A1GAAGLAHSD17B10 | |
| SCHEMBL5169967 | 0.79 | NOS3 (0.52) | KDM4ENOS3NOS2MAPT | |
| SCHEMBL480040 | 0.79 | NAPRT (0.55) | KDM4EALDH1A1NOS3NOS2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-10-17 | — | — | US | disclosed |
| WO-2024178127-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| CN-114341127-A | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| EP-2671582-B1 | RING-FUSED HETEROCYCLIC DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-9000186-B2 | Ring-fused heterocyclic derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140038941-A1 | RING-FUSED HETEROCYCLIC DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-02-06 | — | — | US | disclosed |
| EP-2671582-A1 | RING-FUSED HETEROCYCLIC DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | KDM4E 489/4885ALDH1A1 4349/4885GAA 4379/4885 |
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | KDM4E 1701/4885ALDH1A1 290/4885GAA 813/4885 |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | KDM4E 2401/4885ALDH1A1 3336/4885GAA 2071/4885 |
| US-20140038941-A1 | RING-FUSED HETEROCYCLIC DERIVATIVE | CACNA1E, SLC8A1, CALCR | KDM4E 3779/4885ALDH1A1 3112/4885GAA 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.